JP5969484B2 - 抗血栓性材料および医療用具 - Google Patents
抗血栓性材料および医療用具 Download PDFInfo
- Publication number
- JP5969484B2 JP5969484B2 JP2013529949A JP2013529949A JP5969484B2 JP 5969484 B2 JP5969484 B2 JP 5969484B2 JP 2013529949 A JP2013529949 A JP 2013529949A JP 2013529949 A JP2013529949 A JP 2013529949A JP 5969484 B2 JP5969484 B2 JP 5969484B2
- Authority
- JP
- Japan
- Prior art keywords
- repeating unit
- meth
- mol
- polymer
- daam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 title claims description 110
- 230000002965 anti-thrombogenic effect Effects 0.000 title claims description 25
- 230000002785 anti-thrombosis Effects 0.000 claims description 46
- 239000003146 anticoagulant agent Substances 0.000 claims description 46
- 239000000758 substrate Substances 0.000 claims description 43
- 239000003431 cross linking reagent Substances 0.000 claims description 28
- -1 allyl sulfate Chemical compound 0.000 claims description 25
- 239000000178 monomer Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000011247 coating layer Substances 0.000 claims description 15
- 239000010410 layer Substances 0.000 claims description 15
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 12
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 10
- 239000007795 chemical reaction product Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 claims description 8
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 8
- AUZRCMMVHXRSGT-UHFFFAOYSA-N 2-methylpropane-1-sulfonic acid;prop-2-enamide Chemical compound NC(=O)C=C.CC(C)CS(O)(=O)=O AUZRCMMVHXRSGT-UHFFFAOYSA-N 0.000 claims description 6
- VEWLDLAARDMXSB-UHFFFAOYSA-N ethenyl sulfate;hydron Chemical compound OS(=O)(=O)OC=C VEWLDLAARDMXSB-UHFFFAOYSA-N 0.000 claims description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- QENRKQYUEGJNNZ-UHFFFAOYSA-N 2-methyl-1-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound CC(C)C(S(O)(=O)=O)NC(=O)C=C QENRKQYUEGJNNZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 description 69
- 239000000243 solution Substances 0.000 description 40
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 description 35
- 238000000034 method Methods 0.000 description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- 238000000576 coating method Methods 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 239000002585 base Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000011248 coating agent Substances 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- 230000014508 negative regulation of coagulation Effects 0.000 description 22
- 229920001577 copolymer Polymers 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 19
- 238000006116 polymerization reaction Methods 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 230000003214 anti-biofilm Effects 0.000 description 14
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 229960002897 heparin Drugs 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 229920005604 random copolymer Polymers 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 7
- 235000010265 sodium sulphite Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 239000004800 polyvinyl chloride Substances 0.000 description 6
- 229920000915 polyvinyl chloride Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- MNCGMVDMOKPCSQ-UHFFFAOYSA-M sodium;2-phenylethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=CC1=CC=CC=C1 MNCGMVDMOKPCSQ-UHFFFAOYSA-M 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 238000003618 dip coating Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 229910000831 Steel Inorganic materials 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 230000032770 biofilm formation Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000007334 copolymerization reaction Methods 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000000635 electron micrograph Methods 0.000 description 4
- 125000003700 epoxy group Chemical group 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000003505 polymerization initiator Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229950003937 tolonium Drugs 0.000 description 3
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- HFCUBKYHMMPGBY-UHFFFAOYSA-N 2-methoxyethyl prop-2-enoate Chemical compound COCCOC(=O)C=C HFCUBKYHMMPGBY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000002473 artificial blood Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 229910001411 inorganic cation Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DZSVIVLGBJKQAP-UHFFFAOYSA-N 1-(2-methyl-5-propan-2-ylcyclohex-2-en-1-yl)propan-1-one Chemical compound CCC(=O)C1CC(C(C)C)CC=C1C DZSVIVLGBJKQAP-UHFFFAOYSA-N 0.000 description 1
- PWDRWKOQZXJKFA-UHFFFAOYSA-N 2,2-dimethyl-3-oxopent-4-ene-1-sulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)C(=O)C=C PWDRWKOQZXJKFA-UHFFFAOYSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- WFUGQJXVXHBTEM-UHFFFAOYSA-N 2-hydroperoxy-2-(2-hydroperoxybutan-2-ylperoxy)butane Chemical compound CCC(C)(OO)OOC(C)(CC)OO WFUGQJXVXHBTEM-UHFFFAOYSA-N 0.000 description 1
- FKOZPUORKCHONH-UHFFFAOYSA-N 2-methylpropane-1-sulfonic acid Chemical compound CC(C)CS(O)(=O)=O FKOZPUORKCHONH-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000007754 air knife coating Methods 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium peroxydisulfate Substances [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 1
- VAZSKTXWXKYQJF-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)OOS([O-])=O VAZSKTXWXKYQJF-UHFFFAOYSA-N 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010539 anionic addition polymerization reaction Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 238000010538 cationic polymerization reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000012986 chain transfer agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229910000361 cobalt sulfate Inorganic materials 0.000 description 1
- 229940044175 cobalt sulfate Drugs 0.000 description 1
- KTVIXTQDYHMGHF-UHFFFAOYSA-L cobalt(2+) sulfate Chemical compound [Co+2].[O-]S([O-])(=O)=O KTVIXTQDYHMGHF-UHFFFAOYSA-L 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007766 curtain coating Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 108010041201 prothrombin fragment 1 Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007717 redox polymerization reaction Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/068—Use of macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/064—Use of macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Materials For Medical Uses (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
Description
で示されるダイアセトン(メタ)アクリルアミド由来の繰り返し単位(A)、ならびに、25〜75モル%の2−(メタ)アクリルアミド−2−メチル−プロパンスルホン酸、硫酸ビニル、硫酸アリル、スチレンスルホン酸、スルホエチル(メタ)アクリレート、およびスルホプロピル(メタ)アクリレートよりなる群から選択される少なくとも1つのスルホン酸基を分子内に有するモノマーまたはその塩由来の繰り返し単位(B)[繰り返し単位(A)および繰り返し単位(B)の合計量は100モル%である]から構成される共重合体を含む。
で示されるダイアセトン(メタ)アクリルアミド由来の繰り返し単位(A)(以下、単に「繰り返し単位(A)」とも称する)、ならびに、25〜75モル%の2−(メタ)アクリルアミド−2−メチル−プロパンスルホン酸、硫酸ビニル、硫酸アリル、スチレンスルホン酸、スルホエチル(メタ)アクリレート、およびスルホプロピル(メタ)アクリレートよりなる群から選択される少なくとも1つのスルホン酸基を分子内に有するモノマーまたはその塩由来の繰り返し単位(B)(以下、単に「繰り返し単位(B)」とも称する)[繰り返し単位(A)および繰り返し単位(B)の合計量は100モル%である]から構成される共重合体を含む。
で示される2−(メタ)アクリルアミド−2−メチル−プロパンスルホン酸、もしくは、下記式(3):
2−アクリルアミド−2−メチル−プロパンスルホン酸(AMPS) 14.9g(72mmol)とダイアセトンアクリルアミド(DAAM) 6.1g(36mmol)とを純水100mLに溶解し、四つ口フラスコに入れて50℃のオイルバス中で1時間窒素バブリングした。その後、過硫酸カリウム(KPS) 0.146g(AMPSとDAAMの総モル量に対して0.5mol%)と亜硫酸ナトリウム 0.068g(KPSと等モル)とを水2mLに溶解して窒素パージした溶液を添加し、50℃で5時間撹拌させて重合した。
2−アクリルアミド−2−メチル−プロパンスルホン酸(AMPS) 11.1g(54mmol)とDAAM 9.12g(54mmol)とを純水100mLに溶解し、四つ口フラスコに入れて50℃のオイルバス中で1時間窒素バブリングした。その後、過硫酸カリウム(KPS) 0.146g(AMPSとDAAMの総モル量に対して0.5mol%)と亜硫酸ナトリウム 0.068g(KPSと等モル)とを水2mLに溶解して窒素パージした溶液を添加し、50℃で5時間撹拌させて重合した。
2−アクリルアミド−2−メチル−プロパンスルホン酸(AMPS) 7.47g(36mmol)とDAAM 12.2g(72mmol)とを純水100mLに溶解し、四つ口フラスコに入れて50℃のオイルバス中で1時間窒素バブリングした。その後、過硫酸カリウム(KPS) 0.146g(AMPSとDAAMの総モル量に対して0.5mol%)と亜硫酸ナトリウム 0.068g(KPSと等モル)とを水2mLに溶解して窒素パージした溶液を添加し、50℃で5時間撹拌させて重合した。
2−アクリルアミド−2−メチル−プロパンスルホン酸(AMPS) 2.49g(12mmol)とDAAM 16.25g(96mmol)とを純水100mLに溶解し、四つ口フラスコに入れて50℃のオイルバス中で1時間窒素バブリングした。その後、過硫酸カリウム(KPS) 0.146g(AMPSとDAAMの総モル量に対して0.5mol%)と亜硫酸ナトリウム 0.068g(KPSと等モル)とを水2mLに溶解して窒素パージした溶液を添加し、50℃で5時間撹拌させて重合した。
2−アクリルアミド−2−メチル−プロパンスルホン酸(AMPS) 19.9g(96mmol)とDAAM 2.03g(12mmol)とを純水100mLに溶解し、四つ口フラスコに入れて50℃のオイルバス中で1時間窒素バブリングした。その後、過硫酸カリウム(KPS) 0.146g(AMPSとDAAMの総モル量に対して0.5mol%)と亜硫酸ナトリウム 0.068g(KPSと等モル)とを水2mLに溶解して窒素パージした溶液を添加し、50℃で5時間撹拌させて重合した。
アクリル酸2−メトキシエチル(MEA)26.3g(0.2mol)をトルエン100mLに溶解し、四つ口フラスコに入れて80℃のオイルバス中で1時間窒素バブリングした。その後、アゾビスイソブチロニトリル0.03gをトルエン2mLに溶解して窒素パージした溶液を添加し、80℃で8時間撹拌させて重合した。
スチレンスルホン酸ナトリウム 7.1g(118mmol)とDAAM 2.9g(59mmol)とを純水47mLに溶解し、四つ口フラスコに入れて50℃のオイルバス中で1時間窒素バブリングした。その後、過硫酸カリウム(KPS) 0.069g(スチレンスルホン酸ナトリウムとDAAMの総モル量に対して0.05mol%)と亜硫酸ナトリウム 0.032g(KPSと等モル)とを水3mLに溶解して窒素パージした溶液を添加し、50℃で窒素バブリングを継続しながら5時間撹拌させて重合した。
(試験1−1.抗凝固時間(活性化部分トロンボプラスチン時間(APTT))測定)
実施例1〜3、比較例1および比較例3で得たポリマーを用いて、下記方法によりAPTT測定を行った。
実施例4で得たポリマーを用いて、下記方法によりAPTT測定を行った。
(1)コート溶液の調製
実施例1〜3、および比較例2で得たポリマーを1重量%の濃度で水/メタノール(1/1体積比)混合溶液に溶解し、架橋剤としてアジピン酸ジヒドラジドをポリマーと等量(ポリマーそのものの重量と同重量)を添加し、コート溶液を調製した。
このコート溶液を、ポリプロピレン製のシート基材にディップコートした後、常温で乾燥することにより、基材上にポリマーのコート層を形成した。
(1)コート溶液の調製
実施例4で得たポリマーを1重量%の濃度で、水:エタノール:メタノール=6:3:1(体積比)の混合溶媒に溶解し、架橋剤としてアジピン酸ジヒドラジドをポリマーと等量(ポリマーそのものの重量と同重量)を添加し、コート溶液を調製した。
このコート溶液をポリプロピレン製のシート基材にディップコートした後、常温で3時間乾燥することにより、基材上にポリマーのコート層を形成した。
(1)コート溶液の調製
実施例4で得たポリマーを1重量%の濃度で、メタノール:水=5:1(体積比)の混合溶媒に溶解し、架橋剤としてアジピン酸ジヒドラジドをポリマーと等量(ポリマーそのものの重量と同重量)を添加し、コート溶液を調製した。
このコート溶液を基材であるポリ塩化ビニルチューブにディップコートした後、常温で3時間乾燥することにより、基材上にポリマーのコート層を形成した。
内径6mm、外径9mmの軟質PVCチューブの内面に実施例1〜3、比較例3のポリマーをそれぞれコートした。
実施例3および比較例3で得たポリマーを1重量%の濃度で、水/メタノール(1/1体積比)混合溶液に溶解した。これを人工肺(テルモ社製)に血液インポート側から充填し、120秒間静置した後に除去、送風乾燥した。
実施例3および比較例3で得たポリマーを1重量%の濃度で、水/メタノール(1/1体積比)混合溶液に溶解した。これを外径2mmのポリウレタン製チューブの外面にディップコートした後、室温で12時間以上、乾燥した。その後、ヘパリン加新鮮血中に2時間静置した後に生理食塩水で洗浄し、グルタルアルデヒドで固定し、上記外面を電子顕微鏡で観察した。
実施例3および比較例3で得たポリマーを1重量%の濃度で、水/メタノール(1/1体積比)混合溶液に溶解した。これを、2cm×5cmのポリウレタン製シートの表面にディップコートし、室温で12時間以上、乾燥した。
Claims (7)
- 75〜25モル%の下記式(1):
で示されるダイアセトン(メタ)アクリルアミド由来の繰り返し単位(A)、ならびに、25〜75モル%の2−(メタ)アクリルアミド−2−メチル−プロパンスルホン酸、硫酸ビニル、硫酸アリル、スチレンスルホン酸、スルホエチル(メタ)アクリレート、およびスルホプロピル(メタ)アクリレートよりなる群から選択される少なくとも1つのスルホン酸基を分子内に有するモノマーまたはその塩由来の繰り返し単位(B)[繰り返し単位(A)および繰り返し単位(B)の合計量は100モル%である]から構成される共重合体を含む抗血栓性材料。 - 前記繰り返し単位(B)は下記式(2):
で示される2−(メタ)アクリルアミド−2−メチル−プロパンスルホン酸またはその塩由来の繰り返し単位を含む、請求項1に記載の抗血栓性材料。 - 前記式(1)中、R1は水素原子であり、前記式(2)中、R2は水素原子である、請求項2に記載の抗血栓性材料。
- 前記繰り返し単位(A)と前記繰り返し単位(B)とのモル組成比(A:B)が、30:70〜50:50である、請求項1〜3のいずれか1項に記載の抗血栓性材料。
- 基材と、
前記基材表面を被覆する、請求項1〜4のいずれか1項に記載の抗血栓性材料を含むコート層と、を有する医療用具。 - 前記コート層が、請求項1〜4のいずれか1項に記載の抗血栓性材料と架橋剤との反応生成物で形成されている請求項5に記載の医療用具。
- 前記架橋剤が、一分子あたり少なくとも2個のヒドラジン残基を有するヒドラジド化合物である請求項6に記載の医療用具。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011180925 | 2011-08-22 | ||
JP2011180925 | 2011-08-22 | ||
JP2011245614 | 2011-11-09 | ||
JP2011245614 | 2011-11-09 | ||
JP2012026401 | 2012-02-09 | ||
JP2012026401 | 2012-02-09 | ||
PCT/JP2012/069739 WO2013027556A1 (ja) | 2011-08-22 | 2012-08-02 | 抗血栓性材料および医療用具 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2013027556A1 JPWO2013027556A1 (ja) | 2015-03-19 |
JP5969484B2 true JP5969484B2 (ja) | 2016-08-17 |
Family
ID=47746307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529949A Active JP5969484B2 (ja) | 2011-08-22 | 2012-08-02 | 抗血栓性材料および医療用具 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9415144B2 (ja) |
EP (1) | EP2749302B1 (ja) |
JP (1) | JP5969484B2 (ja) |
WO (1) | WO2013027556A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2684150C (en) | 2007-05-14 | 2016-10-04 | Research Foundation Of State University Of New York | Decenoic acid dispersion inducers in the treatment of biofilms |
JP2015097550A (ja) * | 2012-03-13 | 2015-05-28 | テルモ株式会社 | 血液適合性材料および医療用具 |
JP6110186B2 (ja) * | 2013-04-01 | 2017-04-05 | テルモ株式会社 | 潤滑コート剤および医療デバイス |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
EP4065187A1 (en) * | 2019-11-30 | 2022-10-05 | Smart Reactors Service Limited | Coating for medical devices |
GB201917529D0 (en) * | 2019-11-30 | 2020-01-15 | Smart Reactors Service Ltd | Coating for medical devices |
CN111330090B (zh) * | 2020-03-02 | 2022-04-05 | 中国科学院宁波材料技术与工程研究所 | 一种血液透析器的表面抗凝修饰方法及其应用 |
GB202107817D0 (en) * | 2021-06-01 | 2021-07-14 | Smart Reactors Service Ltd | Coating for medical devices |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663364A (en) * | 1984-09-05 | 1987-05-05 | Kao Corporation | Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder |
US4731080A (en) * | 1985-01-18 | 1988-03-15 | Galin Miles A | Coated intraocular lens |
WO1986007541A1 (en) * | 1985-06-19 | 1986-12-31 | Yasushi Zyo | Composition which can impart antithrombotic ability and medical apparatus to be in contact with blood |
US4739008A (en) * | 1986-11-18 | 1988-04-19 | Exxon Chemical Patents Inc. | Bi-phase initiator system for water-in-oil emulsion polymers |
US5278200A (en) * | 1992-10-30 | 1994-01-11 | Medtronic, Inc. | Thromboresistant material and articles |
JP3818684B2 (ja) | 1995-11-07 | 2006-09-06 | テルモ株式会社 | 抗血栓性医療用基材及びその製造方法 |
AU4928399A (en) * | 1998-07-27 | 2000-02-21 | M & M Laboratory Co., Ltd. | Ion complex, coating material, and coating method |
JP4185226B2 (ja) * | 1999-11-19 | 2008-11-26 | テルモ株式会社 | 湿潤時に表面が潤滑性を発現する医療用具およびその製造方法 |
US7285590B2 (en) * | 2003-11-13 | 2007-10-23 | Hexion Specialty Chemicals, Inc. | Aqueous dispersions containing multi-stage emulsion polymers |
US20090035350A1 (en) * | 2007-08-03 | 2009-02-05 | John Stankus | Polymers for implantable devices exhibiting shape-memory effects |
JP4941672B2 (ja) * | 2008-03-11 | 2012-05-30 | Jsr株式会社 | 生体関連物質の非特異吸着防止コート剤 |
-
2012
- 2012-08-02 WO PCT/JP2012/069739 patent/WO2013027556A1/ja active Application Filing
- 2012-08-02 JP JP2013529949A patent/JP5969484B2/ja active Active
- 2012-08-02 EP EP12825135.2A patent/EP2749302B1/en active Active
-
2014
- 2014-02-21 US US14/186,124 patent/US9415144B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2013027556A1 (ja) | 2015-03-19 |
EP2749302A4 (en) | 2015-04-01 |
US20140172117A1 (en) | 2014-06-19 |
EP2749302B1 (en) | 2018-07-18 |
EP2749302A1 (en) | 2014-07-02 |
WO2013027556A1 (ja) | 2013-02-28 |
US9415144B2 (en) | 2016-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5969484B2 (ja) | 抗血栓性材料および医療用具 | |
JP6495241B2 (ja) | 医療用具の製造方法および医療用具 | |
JP5155146B2 (ja) | 挿入可能な医療器具用の柔軟性ポリマー被膜 | |
US10022478B2 (en) | Medical device | |
WO2000061205A1 (en) | Lubricious coatings for medical devices | |
WO2016084716A1 (ja) | 医療用具およびその製造方法 | |
JP4273965B2 (ja) | 抗血栓性組成物およびそれを有する医療用具 | |
US9956324B2 (en) | Medical material, and medical device using the medical material | |
JP2014147638A (ja) | 医療用具の製造方法 | |
JP6456196B2 (ja) | 抗血栓性接着用組成物、ならびに該抗血栓性接着用組成物を利用した医療用具およびその製造方法 | |
JP2015097550A (ja) | 血液適合性材料および医療用具 | |
JP3818684B2 (ja) | 抗血栓性医療用基材及びその製造方法 | |
JP2014147639A (ja) | 医療用具 | |
JP6278731B2 (ja) | 抗血栓性医療材料、および該医療材料を利用した医療用具 | |
JP6426625B2 (ja) | 抗血栓性医療材料、および該医療材料を利用した医療用具 | |
WO2014123077A1 (ja) | 医療用コーティング材料および医療用具 | |
JP4347927B2 (ja) | 抗血栓性医療用具の製造方法 | |
JP4691745B2 (ja) | 抗菌性抗血栓性材料のコーティング方法 | |
JP2012029831A (ja) | ヘパリンコーティング剤及び医療用具 | |
JPWO2020175329A1 (ja) | 医療用具の製造方法および医療用具 | |
JP2012029830A (ja) | ヘパリンコーティング剤及び医療用具 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160301 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160628 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160707 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5969484 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |